Wheaton, Maryland Site — Wheaton, Maryland

Wheaton, Maryland Site is a clinical research site located in Wheaton, Maryland, United States 20902.

Crixeo Clinical Trials Trust Score: 4/100 (FAILING). This profile has not yet been claimed by the site owner.

Wheaton, Maryland Site has participated in 1 clinical trials.

Therapeutic areas: Systemic Lupus Erythematosus.

Sponsors: Vor Biopharma.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Wheaton

Browse all research sites in Maryland · View every site in Wheaton

• The Center for Rheumatology and Bone Research
• Research Site
• GSK Investigational Site
• Institute for Asthma and Allergy
• Pfizer Investigational Site
• Novartis Investigative Site
• Center for Rheumatology and Bone Research
• Institute for Asthma and Allergy PC
• Investigational Site Number 840013
• Center For Rheumatology & Bone Research
• Maryland Oncology Hematology, P.A.
• ADARx Clinical Site

Sponsor Feasibility Report

Trust Score: 4/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Wheaton, Maryland Site?

Wheaton, Maryland Site has a Crixeo Trust Score of 4/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Wheaton, Maryland Site conducted?

Wheaton, Maryland Site has 1 clinical trials on record. Their work covers Systemic Lupus Erythematosus.

Is Wheaton, Maryland Site accredited by Crixeo Clinical Trials?

Wheaton, Maryland Site has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Wheaton, Maryland Site?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.